First step: testing drug safety in people with liver issues
NCT ID NCT06376474
First seen Jan 05, 2026 · Last updated Apr 16, 2026 · Updated 14 times
Summary
This early-stage study aims to understand how a potential psoriasis medication, called Hemay005, is processed by the body in people with different levels of liver function. It will enroll 24 adults, some with mild or moderate liver impairment and others with normal liver function, who will take a single dose. The main goal is to measure drug levels in the blood to help determine safe dosing for future patients with liver conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital of Tongji Medical College; Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.